Abstract:Hepatocellular carcinoma (HCC) represents one of the few cancers for which locoregional treatments are recognised as being able to cure and/or prolong survival and are included in international guidelines. This is due to the unique nature of HCC, in most cases occurring in patients with underlying virus- or alcohol-related cirrhosis. The treatment choice in patients with HCC is therefore driven not only by tumour staging, as in the great majority of cancers, but also by careful evaluation of liver function and physical status. Another specific feature of HCC is that it is the only tumour that can be cured by organ transplantation, with the aim of treating both the cancer and underlying liver disease. These characteristics configure a complex scenario and prompt the need for close cooperation among interventional oncologists, surgeons, hepatologists, and anaesthesiologists. In patients with limited hepatic disease, preserved hepatic function and good performance status, categorised as very early and early-stage HCC according to the Barcelona Clinic Liver Cancer (BCLC) classification, image-guided tumour ablation is included among the curative treatments. More than half of patients with HCC are, however, diagnosed late, despite the widespread implementation of surveillance programmes, when curative treatments cannot be applied. For patients presenting with multinodular HCC and relatively preserved liver function, absence of cancer-related symptoms, and no evidence of vascular invasion or extrahepatic spread transcatheter arterial chemoembolisation (TACE) is the current standard of care. Although anti-tumour activity and promising survival results has been reported in cohorts of patients with advanced HCC treated with radio-embolisation, systemic treatment with the multi-kinase inhibitor, sorafenib, is still recommended for patients at this stage. In this article, current treatment strategies for HCC according to tumour stage are discussed, underlining the latest advances in the literature and technical developments.

Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma

Emerging Biomolecules for Practical Theranostics of Liver Hepatocellular Carcinoma.

Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status

Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma

Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies

The current landscape of therapies for hepatocellular carcinoma

Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

Loco-regional treatment of HCC: current status

Locoregional Therapies for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease

Emerging Therapies for Hepatocellular Carcinoma (HCC)

Tumor-Associated Neutrophils: an Emerging Player in the Immune Microenvironment of Hepatocellular Carcinoma

A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma

Emerging Agents and Regimens for Hepatocellular Carcinoma.

Current approaches to the treatment of early hepatocellular carcinoma.

New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma

Recent treatments to Hepatocellular Carcinoma Cancer(HCC): update and outlook

Hepatocellular Carcinoma: The Evolving Role of Systemic Therapies as a Bridging Treatment to Liver Transplantation

Technology Insight: image-guided therapies for hepatocellular carcinoma—intra-arterial and ablative techniques

New Progress of Non-Surgical Treatments for Hepatocellular Carcinoma.

Chemoembolization Plus Ablation: Current Status

Expanded Use of Aggressive Therapies Improves Survival in Early and Intermediate Hepatocellular Carcinoma